Akshanth R. Polepally
AbbVie (United States)(US)
Publications by Year
Research Areas
Hepatitis C virus research, Peptidase Inhibition and Analysis, HIV/AIDS drug development and treatment, CAR-T cell therapy research, Multiple Myeloma Research and Treatments
Most-Cited Works
- → Sustained virologic response of 100% in HCV genotype 1b patients with cirrhosis receiving ombitasvir/paritaprevir/r and dasabuvir for 12 weeks(2015)161 cited
- → Drug-drug interaction profile of the all-oral anti-hepatitis C virus regimen of paritaprevir/ritonavir, ombitasvir, and dasabuvir(2015)125 cited
- → Ombitasvir/paritaprevir/r and dasabuvir plus ribavirin in HCV genotype 1-infected patients on methadone or buprenorphine(2015)118 cited
- → A Phase I First-in-Human Study of ABBV-383, a B-Cell Maturation Antigen × CD3 Bispecific T-Cell Redirecting Antibody, in Patients With Relapsed/Refractory Multiple Myeloma(2022)117 cited
- → Model‐based lamotrigine clearance changes during pregnancy: clinical implication(2014)94 cited
- → First-in-Human Phase I Study of ABBV-085, an Antibody–Drug Conjugate Targeting LRRC15, in Sarcomas and Other Advanced Solid Tumors(2021)70 cited
- → Clinical Pharmacology of Elagolix: An Oral Gonadotropin-Releasing Hormone Receptor Antagonist for Endometriosis(2019)62 cited
- → A Phase 1 First-in-Human Study of Tnb-383B, a BCMA x CD3 Bispecific T-Cell Redirecting Antibody, in Patients with Relapsed/Refractory Multiple Myeloma(2021)48 cited
- → Drug Interactions with the Direct-Acting Antiviral Combination of Ombitasvir and Paritaprevir-Ritonavir(2015)42 cited
- → Dosing Recommendations for Concomitant Medications During 3D Anti-HCV Therapy(2015)31 cited